U.S. markets closed
  • S&P Futures

    4,459.75
    +14.00 (+0.31%)
     
  • Dow Futures

    34,813.00
    +139.00 (+0.40%)
     
  • Nasdaq Futures

    15,354.25
    +35.50 (+0.23%)
     
  • Russell 2000 Futures

    2,254.90
    +10.90 (+0.49%)
     
  • Crude Oil

    74.78
    +0.80 (+1.08%)
     
  • Gold

    1,752.70
    +1.00 (+0.06%)
     
  • Silver

    22.47
    +0.04 (+0.18%)
     
  • EUR/USD

    1.1725
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.4600
    +0.0500 (+3.55%)
     
  • Vix

    17.75
    -0.88 (-4.72%)
     
  • GBP/USD

    1.3672
    -0.0009 (-0.06%)
     
  • USD/JPY

    110.6870
    +0.0020 (+0.00%)
     
  • BTC-USD

    43,224.16
    +607.51 (+1.43%)
     
  • CMC Crypto 200

    1,076.74
    -26.32 (-2.39%)
     
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • Nikkei 225

    30,299.16
    +50.35 (+0.17%)
     

Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Aptorum Group Limited (NASDAQ: APM) announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus.

  • Specifically, two additional cohorts (Cohort C & D) of the single ascending dose portion of the Phase 1 trial in healthy subjects have been completed with no serious adverse events observed.

  • No subjects were dropped out of the studies, and no serious adverse events were observed.

  • Additionally, no clinically relevant changes regarding vital signs, electrocardiogram, clinical laboratory test results and physical examinations were observed compared to baselines.

  • The single ascending dose is still ongoing to gain additional insights into the effect of food on bioavailability and pharmacokinetics.

  • On this basis, the company plans to proceed to the multiple ascending dose part in 3Q of 2021.

  • In May, the company completed two initial cohorts of the single-dose ascending dose portion of the Phase 1 trial.

  • Price Action: APM shares are up 4.64% at $3.16 during the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.